Vanguard Global Advisers
TYRA icon

Vanguard Global Advisers’s Tyra Biosciences TYRA Stock Holding History

Vanguard Global Advisers’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
20,154
+4,674
+30% +$155K ﹤0.01% 1985
2026
Q1 		$593K Buy
+15,480
New +$501K ﹤0.01% 1959

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Global Advisers's TYRA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Tyra Biosciences (TYRA) stake by 30% in Q2 2026, buying an estimated $155K and bringing the position to 20,154 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #1985.

Vanguard Global Advisers first reported a position in TYRA in Q1 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Vanguard Global Advisers held 20,154 shares of Tyra Biosciences worth $644K as of Q2 2026.
  • Vanguard Global Advisers bought 4,674 Tyra Biosciences shares in Q2 2026, an estimated $155K.
  • Tyra Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1985 holding.
  • Vanguard Global Advisers first reported a position in Tyra Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.